ReviewJournal of diabetes research2015
Mesenchymal Stem Cells: Rising Concerns over Their Application in Treatment of Type One Diabetes Mellitus.
Review in Journal of diabetes research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Pooled it
- Review
- Advancing toward a curative frontier: an updated narrative review on stem-cell therapy in pediatric type 1 diabetes.World journal of pediatrics : WJP · 2025Review
- The Bone Marrow Microenvironment in Immune-Mediated Inflammatory Diseases: Implications for Mesenchymal Stromal Cell-Based Therapies.Stem cells translational medicine · 2024Review
- Advanced therapy to cure diabetes: mission impossible is now possible?Frontiers in cell and developmental biology · 2024Review
- Mesenchymal Stem Cell-Based Therapy as a New Approach for the Treatment of Systemic Sclerosis.Clinical reviews in allergy & immunology · 2023Review
- BM-MSCs alleviate diabetic nephropathy in male rats by regulating ER stress, oxidative stress, inflammation, and apoptotic pathways.Frontiers in pharmacology · 2023Article
- Administration of mesenchymal stem cells in diabetic kidney disease: mechanisms, signaling pathways, and preclinical evidence.Molecular and cellular biochemistry · 2022Review
- Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes.Stem cells international · 2022Review
- Autophagy Involves in Differentiation of Insulin-Secreting Cells from Adipose Derived Stem Cells.Cell journal · 2021Article
- Applications of stem cells and bioprinting for potential treatment of diabetes.World journal of stem cells · 2019Review
- A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies.Stem cell investigation · 2019Review
- Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?Frontiers in immunology · 2019Review
- Effect of Stem Cells and Gene Transfected Stem Cells Therapy on the Pancreas of Experimentally Induced Type 1 Diabetes.International journal of stem cells · 2018Article
- Autophagy induces G0/G1 arrest and apoptosis in menstrual blood-derived endometrial stem cells via GSK3-β/β-catenin pathway.Stem cell research & therapy · 2018Article
- Mesenchymal Stem Cells as New Therapeutic Approach for Diabetes and Pancreatic Disorders.International journal of molecular sciences · 2018Review
- Vascular stem/progenitor cells: functions and signaling pathways.Cellular and molecular life sciences : CMLS · 2018Review
- Evaluation of Oxidative Stress and Mitophagy during Adipogenic Differentiation of Adipose-Derived Stem Cells Isolated from Equine Metabolic Syndrome (EMS) Horses.Stem cells international · 2018Article
- High glucose induces the aging of mesenchymal stem cells via Akt/mTOR signaling.Molecular medicine reports · 2017Article
- Infusion of umbilical cord mesenchymal stem cells alleviates symptoms of ankylosing spondylitis.Experimental and therapeutic medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes mellitus (T1DM) is an autoimmune disorder that leads to beta cell destruction and lowered insulin production. In recent years, stem cell therapies have opened up new horizons to treatment of diabetes mellitus. Among all kinds of stem cells, mesenchymal stem cells (MSCs) have been shown to be an interesting therapeutic option based on their immunomodulatory properties and differentiation potentials confirmed in various experimental and clinical trial studies. In this review, we discuss MSCs differential potentials in differentiation into insulin-producing cells (IPCs) from various sources and also have an overview on currently understood mechanisms through which MSCs exhibit their immunomodulatory effects. Other important issues that are provided in this review, due to their importance in the field of cell therapy, are genetic manipulations (as a new biotechnological method), routes of transplantation, combination of MSCs with other cell types, frequency of transplantation, and special considerations regarding diabetic patients' autologous MSCs transplantation. At the end, utilization of biomaterials either as encapsulation tools or as scaffolds to prevent immune rejection, preparation of tridimensional vascularized microenvironment, and completed or ongoing clinical trials using MSCs are discussed. Despite all unresolved concerns about clinical applications of MSCs, this group of stem cells still remains a promising therapeutic modality for treatment of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.